Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Pulmicort Generics Win a Negative for Teva, Canaccord Says

Don't Miss Out —
Follow us on:

April 2 (Bloomberg) -- U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e-mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt **NOTE: AstraZeneca May Appeal U.S. Patent Ruling on Pulmicort Respules NSN MKMET76JTSEN <GO>

To contact the reporter on this story: Leslie Picker in New York at

To contact the editor responsible for this story: Emma O’Brien at